An Acute Retinal Model for Evaluating Blood Retinal Barrier Breach and Potential Drugs for Treatment.
A low-cost, easy-to-use and powerful model system is established to evaluate potential treatments that could ameliorate blood retinal barrier breach. An inflammatory factor, histamine, is demonstrated to compromise vessel integrity in the cultured retina through positive staining of IgG outside of the blood vessels. The effects of histamine itself and those of candidate drugs for potential treatments, such as lipoxin A4, are assessed using three parameters: blood vessel leakage via IgG immunostaining, activation of Müller cells via GFAP staining and change in neuronal dendrites through staining for MAP2. Furthermore, the layered organization of the retina allows a detailed analysis of the processes of Müller and ganglion cells, such as changes in width and continuity. While the data presented is with swine retinal culture, the system is applicable to multiple species. Thus, the model provides a reliable tool to investigate the early effects of compromised retinal vessel integrity on different cell types and also to evaluate potential drug candidates for treatment.
Graduate School of Biomedical Sciences, Rowan University.
Hao
H
Wu
Department of Cell Biology, Rowan University School of Osteopathic Medicine.
Ana R
AR
Rodriguez
Department of Cell Biology, Rowan University School of Osteopathic Medicine.
Bernd W
BW
Spur
Graduate School of Biomedical Sciences, Rowan University; Department of Cell Biology, Rowan University School of Osteopathic Medicine; vvenkat2007@gmail.com.
Venkat
V
Venkataraman
D000818:Animals; D001813:Blood-Retinal Barrier / Q000187:drug effects* / Q000473:pathology*; D063928:Ependymoglial Cells / Q000473:pathology; D006632:Histamine / Q000494:pharmacology; D012160:Retina / Q000187:drug effects / Q000473:pathology; D012171:Retinal Vessels / Q000473:pathology; D013552:Swine
D006632:Histamine
Exp Eye Res. 2005 Feb;80(2):249-58
15670803
J Pharm Pharmacol. 2014 Jul;66(7):954-60
24697218
J Alzheimers Dis. 2011;25(4):605-22
21483091
Neurosci Lett. 1993 Feb 5;150(1):17-20
8469396
Eur J Ophthalmol. 2011;21 Suppl 6:S3-9
23264323
Biol Pharm Bull. 2006 Oct;29(10):2148-50
17015969
Nature. 2014 Jun 5;510(7503):92-101
24899309
Cardiovasc Psychiatry Neurol. 2011;2011:609202
21350721
J Neurosci Methods. 2014 Jul 30;232:165-72
24858797
Am J Pathol. 2010 Apr;176(4):2055
20167871
Tissue Barriers. 2013 Jul 1;1(3):e24782
24665399
Diabetes Metab Res Rev. 1999 Jul-Aug;15(4):261-73
10495475
Fluids Barriers CNS. 2013 Nov 22;10(1):33
24262108
Biomed Res Int. 2015;2015:937148
26697497
Pharm Res. 2010 Dec;27(12):2715-24
20859661
Int Rev Cytol. 1997;172:1-53
9102392
Neurobiol Dis. 2015 Oct;82:593-606
26311408
J Biochem Mol Biol. 2006 Jul 31;39(4):339-45
16889675
Methods Mol Biol. 2011;686:133-48
21082369
J Neurol Neurosurg Psychiatry. 2012 Sep;83(9):917-22
22733082
Prog Retin Eye Res. 2006 Jan;25(1):99-127
16154379
Nat Photonics. 2013 Mar 1;7(3):null
24353743